Business

AmInvestment maintains ‘hold’ call on IHH despite PNB’s share placement news

News report claims PNB to place out some of its shares in the healthcare giant

Updated 4 years ago · Published on 18 Oct 2021 3:20PM

AmInvestment maintains ‘hold’ call on IHH despite PNB’s share placement news
PNB owns around 5.5% stake in IHH, AmInvestment says citing PNB’s annual report 2020. – IHH Healthcare Facebook pic, October 18, 2021

KUALA LUMPUR – AmInvestment Bank Bhd has maintained its “hold” call on IHH Healthcare Bhd (IHH) with an unchanged fair value (FV) of RM6.29.

This was despite news over the weekend that Permodalan Nasional Bhd (PNB) is placing out some of its shares in IHH.

“We are neutral on the news pending a formal announcement on the placement,” it said in a research note today.

According to AmInvestment, local financial news portal The Edge Malaysia Weekly, citing a source familiar with the matter, reported that PNB is placing out some of its shares in IHH.

“Based on its annual report 2020, PNB (through its various funds and subsidiaries) owns around 5.5% stake in IHH. 

The top three shareholders of IHH are Mitsui & Co Ltd (32.90%), Khazanah Nasional Bhd (25.81%) and the Employees Provident Fund (8.30%) as at March 31, 2021,” the research note said.

On IHH’s share performance, AmInvestment said the share price has done well this year with a year-to-date gain of 22% to RM6.72 from RM5.50, supported by its strong earnings before interest, taxes, depreciation, and amortisation (EBITDA) growth in the first half of 2021 (H1 2021) which surged 107% to RM2.07 billion.

On the third quarter of 2021 (Q3 2021) outlook, the investment bank reiterated its view that earnings for the quarter should see a q-o-q decline due to the expectation of lower earnings from its laboratory business.

“Covid-19 daily new cases in India have eased to about 20,000 cases in September from a peak of about 400,000 cases in May.

“This should result in lower revenue for IHH laboratory (business) in Q3 2021 due to fewer Covid-19 tests,” it said.

Although the number of elective surgeries may increase in Q3 2021, it is expected that these would not be enough to offset the impact of the lower earnings from laboratory tests.

According to the investment bank, India has the highest number of labs at over 420, accounting for 87% of the total 483 labs of the company in four key markets.

IHH’s laboratory sector generated a revenue of RM975 million in H1 2021.

At 10.45am, IHH shares rose six sen to RM6.78 with 665,300 shares changing hands. – Bernama, October 18, 2021  

Related News

Malaysia / 3w

Malaysia’s hidden debt trap: When borrowing becomes a way of life

Business / 1mth

KPJ posts strong FY2025 performance, sets sights on next growth phase

Events / 1mth

KPJ rolls out first in-house kidney transplant service, starting with Tawakkal Specialist Hospital

Malaysia / 1mth

Sarawak seeks China collaboration to fix growing doctor shortage

Malaysia / 2mth

No disruptions to healthcare services despite budget cuts, assures minister

Opinion / 5mth

Is our nation heading towards ‘retirement poverty’?

Spotlight

Malaysia

PRNNS: Loke: 'We must win all 11 seats to help PH form state government'

Sports & Fitness

Spain ends Argentina’s World Cup reign with extra-time triumph to reclaim global crown

World

Cat found alive after being buried under Venezuela quake rubble for days (video)

Malaysia

“Resign if you attack fellow Unity Government partners,” Anwar enforces discipline

Malaysia

PH youth wing calls on BN ministers to quit cabinet over PN electoral alliance

Malaysia

Rosmah asks for prayers as Najib prepares for medical procedure

Malaysia

Woman at a loss after fake Hong Kong lawyer offers to recover money from previous scam

You may be interested

Business

Malaysia posts record RM340.9 billion trade in June as exports jump 45.4%

Business

Oil prices rally above US$84 per barrel as US-Iran conflict deepens

Business

Plastics industry faces tough year as raw material volatility add to cost pressures

Business

Oil prices near five-week high as US-Iran conflict fuels supply concerns